Scanfil Oyj · OMXHEX:SCANFL
Scanfil Oyj — Scanfil Oyj Ord — Q2 2026 Earnings Presentation
26 slides from Scanfil Oyj's earnings presentation, Jul 16, 2026
Slide 1: Scanfil Group
Scanfil Group
Slide 2: January-June 2026
January-June 2026 Scanfil Delivers a Strong Q2 as Strategic Progress Reshapes the Company CEO Christophe Sut and CFO Iiris Heiskanen 16 July 2026
Slide 3: 16-Jul-26
16-Jul-26 3
Slide 4: Q2 2026 Highlights
Q2 2026 Highlights Strong Customer Bruker AXS Division EUR 25 Million New Suzhou Expansion Satisfaction Agreement Started • Recommendation and loyalty • Bruker division AXS starts as a • New customer with EUR 25 • Investment of EUR 9 million (NPS) levels remained strong customer to Scanfil million o
Slide 5: Growth Accelerated and Profitability Increased
Growth Accelerated and Profitability Increased Q2 2026 • Strong contribution from acquisitions supported by solid organic growth MEUR 259.0 / 28.1% • Delivered inline with long-term target Turnover / YoY, % • Momentum in organic growth continues 4.7% to support our growth aspirations, Organic growth
Slide 6: Turnover and EBITA
Turnover and EBITA Turnover EBITA 300 20 7,6 259,0 7,4 7,4 7,4 250 7,3 229,1 7,3 7,3 212,3 211,0 15 7,2 7,2 195,5 202,2 192,6 191,3 200 7,0 173,3 7,0 150 10 6,8 6,8 6,6 100 6,5 5 6,4 50 6,2 14,3 12,8 15,5 12,6 14,2 14,1 15,5 15,6 18,6 0 0 6,0 Q2/24 Q2/25 Q2/26 Q2/24 Q2/25 Q2/26 Comparable EBITA, EUR
Slide 7: Americas
8% Americas % of turnover in Q2 2026 21 12 Key takeaways in Q2: 19 10,5 19,8 10 • Organic turnover increased 9,3 17 8,5 17,7 8,3 by 9.5% 8,1 8 15 7,3 7,2 • New product introductions 13 13,9 6,2 6 (NPIs) are starting to 12,7 11 11,7 11,8 4,6 contribute to sales and 4 10,8 profit 9 9,7 8,8 2 • Success
Slide 8: APAC
24 % APAC % of turnover in Q2 2026 Key takeaways in Q2: • Investment of EUR 9 million in Suzhou plant expansion • Doubling the size to nearly 37,000 m² • Expected to be completed in mid-2027 16-Jul-26 8
Slide 9: Central Europe
42 % Central Europe % of turnover in Q2 2026 Key takeaways in Q2: • Organic turnover increased by 4.7% • Polish operations delivered solid organic growth • MB contributed strongly • Restructuring of Germany operations ended 16-Jul-26 9
Slide 10: Northern Europe
27 % Northern Europe % of turnover in Q2 2026 Key takeaways in Q2: • Organic turnover increased by 5.5% • Demand driven by Aerospace & Defense and Energy & Cleantech 16-Jul-26 10
Slide 11: Balanced Customer Portfolio
Balanced Customer Portfolio 10 % 100% 19 % 46% 41% 47% 75% 31 % 50% 42% 46% 42% 25% 40 % 13% 13% 11% 0% % of turnover in H1 2026 2024 2025 H1 2026 Aerospace & Defense Energy & Cleantech The biggest customer TOP10 (ex. biggest) Rest Industrial Medtech & Life Science 16-Jul-26 11
Slide 12: Aerospace & Defense
11 % % of turnover Aerospace & Defense in Q2 2026 Turnover Deals Won Deals 30 28,3 5,3 5 25 21,0 4 1.0M€ Military 20 3 0.9M€ Military 15 2,4 2,5 12,4 9,9 9,8 0.1M€ Military 9,1 9,3 2 10 7,1 7,1 0,9 5 1 0,1 2.5M€ In total 0 0 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q2 Q3 Q4 Q1 25 Q2 Q3 Q4 Q1 26 Q2 24 24 24 25 25
Slide 13: Energy & Cleantech
30 % % of turnover Energy & Cleantech in Q2 2026 Turnover Deals Won Deals 90 45 41,4 80 78,1 40 76,6 73,2 70,8 68,8 35 70 65,9 64,1 61,6 30 27,9 25.0M€ General 60 55,1 24,8 23,9 25 22,8 3.0M€ Energy saving solution 50 19,9 20 18,4 2.6M€ Control system 16,1 40 15 12,1 … … 30 10 41.4M€ In total 20 5 Q
Slide 14: Industrial
40 % % of turnover Industrial in Q2 2026 Turnover Deals Won Deals 110 40 38,6 102,9 100 31,6 93,2 30 91,6 88,9 7.6M€ E-mobility 90 24,8 85,2 83,9 82,9 2.8M€ Housing & Building 80 77,0 20 17,5 74,1 15,3 15,5 13,7 0.9M€ Monitoring Solution 70 11,8 10 6,9 … … 60 13.7M€ In total 50 0 Q2 Q3 Q4 Q1 Q2 Q3 Q
Slide 15: Medtech & Life Science
19 % % of turnover Medtech & Life Science in Q2 2026 Turnover Deals Won Deals 15,3 15 14,3 14,5 49,6 45 11,5 41,7 40,0 6.3M€ Medical AI 38,9 39,4 39,1 38,2 9,5 37,3 10 34,2 8,1 8,1 3.2M€ Medical storage system 35 6,4 1.5M€ Breathing support 4,7 5 25 … … 14.5M€ In total 15 0 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q
Slide 16: Financials
Financials CFO Iiris Heiskanen 16-Jul-26 16
Slide 17: Turnover and Comparable EBITA Bridge
Turnover and Comparable EBITA Bridge Q2 2026 Q2 2026 TURNOVER GROWTH (y-o-y) Comparable EBITA (y-o-y) EUR million EUR million 7.2% 7.0% Turnover increased 28.1 % Comparable EBITA EUR 18.6 million, margin 7.2% • Strong contribution from acquisitions • Increased in all regions • Organic growth was 4.7
Slide 18: Cash Flow and Net Working Capital
Cash Flow and Net Working Capital Operating cash flow EUR 5.9 million in H1 2026 Net working capital increased during H1 • Working capital increased with volume growth • Higher business volume, including acquisitions • Q2 cash flow improved Q/Q • Accounts receivable increased Q/Q, while inventories
Slide 19: Net Debt
Net Debt Net debt at EUR 139.6 million • Increased after acquisition financing and working capital increase • Available liquidity remains strong, EUR 170.3 million in unused credit limits and loan facilities 16-Jul-26 19
Slide 20: Development of Key Figures
Development of Key Figures 16-Jul-26 20
Slide 21: Outlook for 2026
Outlook for 2026 CEO Christophe Sut
Slide 22: Outlook for 2026
Outlook for 2026 Guidance remains unchanged: turnover EUR 940– 1,060 million and comparable EBITA EUR 64–78 million. Solid operational execution, organic growth and major strategic steps in building company’s future. Focus areas: • Drive good momentum in organic growth • Investing in organic and in-
Slide 23: Q&A
Q&A 16-Jul-26 23
Slide 24: Key Takeaways
Key Takeaways • Scanfil delivered a strong turnover growth in Q2, way above its 10% annual growth target • Comparable EBITA margin strengthened to 7.2% in Q2 • All regions delivered positive development, with particularly strong performance in the Americas • Aerospace & Defense showed exceptional gr
Slide 25: Contact information and analysts
Contact information and analysts Carnegie AB, Stockholm Marcus Develius +46 70 848 85 67 marcus.develius@carnegie.se Inderes Oyj CHRISTOPHE SUT, CEO Antti Viljakainen +358 407 318 411 +358 44 591 2216 christophe.sut@scanfil.com antti.viljakainen@inderes.fi Nordea Oyj IIRIS HEISKANEN, CFO Pasi Väisän
Slide 26: Disclaimer
Disclaimer Not to be published or distributed, directly or indirectly, in any country where its distribution or publication is unlawful. Forward looking statements: certain statements in this presentation may constitute "forward- looking" statements which involve known and unknown risks, uncertainti